Table 3.
Antiretroviral provision and management of tuberculosis and malaria
| Total n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| North America N=7 | Latin America N=7 | Asia-Pacific N=20 | Central Africa N=12 | East Africa N=51 | Southern Africa N=16 | West Africa N=15 | All regions N=128 | |
| ART provision | ||||||||
| Current waiting list for ART patients (N,%) | ||||||||
| Yes | – | – | 2 (10%) | 6 (50%) | 23 (45%) | 5 (31%) | 7 (47%) | 43 (34%) |
| No | – | 7 (100%) | 18 (90%) | 6 (50%) | 28 (55%) | 11 (69%) | 7 (47%) | 77 (60%) |
| Missing | 7 (100%) | – | – | – | – | – | 1 (7%) | 8 (6%) |
| Duration of ART medication stock-outs in last 12 months | ||||||||
| 1 day only | – | – | 1 (5%) | 1 (8%) | 1 (2%) | – | – | 3 (2%) |
| 2–7 days | – | – | 1 (5%) | 2 (17%) | 1 (2%) | – | 2 (13%) | 6 (5%) |
| 8–21 days | – | 1 (14%) | – | – | 4 (8%) | – | 2 (13%) | 7 (5%) |
| > 21 days | – | 1 (14%) | – | 3 (25%) | 2 (4%) | – | 2 (13%) | 8 (6%) |
| Duration unknown | – | 1 (14%) | – | 1 (8%) | 1 (2%) | – | 3 (20%) | 12 (9%) |
| No stock-outs | – | 4 (57%) | 17 (85%) | 5 (42%) | 41 (80%) | 6 (38%) | 5 (33%) | 82 (64%) |
| Missing | 7 (100%) | – | 1 (5%) | – | 1 (2%) | 10 (63%) | 1 (7%) | 10 (8%) |
| Tuberculosis | ||||||||
| Location of TB treatment services | ||||||||
| Within onsite HIV care and treatment facility | 1 (14%) | 2 (29%) | 11 (55%) | 4 (33%) | 18 (35%) | 14 (88%) | 11 (73%) | 61 (48%) |
| Onsite TB clinic | 1 (14%) | 5 (71%) | 6 (30%) | 2 (17%) | 24 (47%) | – | 1 (7%) | 39 (30%) |
| Offsite TB clinic | 5 (71%) | – | 3 (15%) | 5 (42%) | 5 (10%) | 2 (13%) | 2 (13%) | 22 (17%) |
| Missing | – | – | – | 1 (8%) | 4 (8%) | – | 1 (7%) | 6 (5%) |
| TB screeninga | ||||||||
| Ask about symptoms as standard part of patient history | 4 (57%) | 6 (86%) | 11 (55%) | 10 (83%) | 39 (76%) | 16 (100%) | 12 (80%) | 98 (77%) |
| Formal questionnaire | 1 (14%) | 1 (14%) | 2 (10%) | 5 (42%) | 30 (59%) | 7 (44%) | 6 (40%) | 52 (41%) |
| Tuberculin skin test | 7 (100%) | 6 (86%) | 6 (30%) | 3 (25%) | 2 (4%) | 7 (44%) | 3 (20%) | 34 (27%) |
| DOTS for adult TB patients | ||||||||
| First 2 months | – | 1 (14%) | 1 (5%) | 4 (33%) | 19 (37%) | 6 (38%) | 6 (40%) | 37 (29%) |
| Entire period | 4 (57%) | 4 (57%) | 9 (45%) | 1 (8%) | 13 (25%) | 6 (38%) | 6 (40%) | 43 (34%) |
| No | 3 (43%) | 2 (29%) | 10 (50%) | 3 (25%) | 12 (24%) | 4 (25%) | 2 (13%) | 36 (28%) |
| Missing | – | – | – | 4 (33%) | 7 (14%) | – | 1 (7%) | 12 (9%) |
| Availability of isoniazid prophylaxis | ||||||||
| For all patients | – | 3 (43%) | 4 (20%) | 1 (8%) | 20 (39%) | 2 (13%) | 2 (13%) | 32 (25%) |
| For some patients | – | 4 (57%) | 11 (55%) | 3 (25%) | 5 (10%) | 13 (81%) | 1 (7%) | 37 (29%) |
| Not available | – | – | 5 (25%) | 7 (58%) | 21 (41%) | 1 (6%) | 12 (80%) | 46 (36%) |
| Missing | 7 (100%) | – | – | 1 (8%) | 5 (10%) | – | – | 13 (10%) |
| Malaria | ||||||||
| Malaria diagnostic methods | ||||||||
| Presumptive diagnosis | – | 1 (14%) | 2 (10%) | 5 (42%) | 35 (69%) | 3 (19%) | 9 (60%) | 55 (43%) |
| Thick smear | – | 5 (71%) | 16 (80%) | 12 (100%) | 45 (88%) | 11 (69%) | 10 (67%) | 99 (77%) |
| Rapid test | – | 1 (14%) | 6 (30%) | 1 (8%) | 13 (25%) | 9 (56%) | 6 (40%) | 36 (28%) |
| Other | – | – | 2 (10%) | – | – | – | 1 (7%) | 3 (2%) |
| Not applicable | – | 2 (29%) | 2 (10%) | – | – | 3 (19%) | – | 7 (5%) |
| Missing | 7 (100%) | – | – | – | – | 1 (6%) | 1 (7%) | 9 (7%) |
| Distribution of free bed netsb | ||||||||
| All patients | – | – | 1 (5%) | – | 7 (14%) | – | 2 (13%) | 10 (8%) |
| Targeted distribution | – | – | 1 (5%) | 2 (17%) | 32 (63%) | – | 1 (7%) | 36 (28%) |
| Not distributed/not applicable | – | 7 (100%) | 18 (90%) | 10 (83%) | 11 (22%) | – | 11 (73%) | 57 (45%) |
| Missing | 7 (100%) | – | – | – | 1 (2%) | 16 (100%) | 1 (7%) | 25 (20%) |
a
TB screening includes screening done on all patients only;
b
one site reported that it did not distribute free bed nets, while also saying it distributed free bed nets to pregnant women and paediatric patients under age 5. This site was only included under targeted distribution.